Rydapt AML
Practical information - Scemblix
Patient Resources - Scemblix
Highlights From ASCO 2022
Ribociclib Breast Cancer Presentations
MONALEESA-2 OS BY DOSE REDUCTION poster discussion | Hart LL In this exploratory analysis of ML-2, 1L RIB + LET maintained OS benefit in postmenopausal pts with HR+, HER2...Twitter Linkedin Facebook Pinterest Google plusMF: patient brochure (FR)
Download French document .field-name-field-np4-expiry-date {display:none;} To receive by post, click on the "Add to card" button belowMF: patient brochure (NL)
Download Dutch document .field-name-field-np4-expiry-date {display:none;} To receive by post, click on the "Add to card" button belowIndication
COMBI-d study
Read more about the COMBI-d study, such as the study design and the most important results.
Study design 1The patient population consisted of 423 patients with unresectable (Stage IIIC) or metastatic (...
Twitter Linkedin Facebook Pinterest Google plusPatient resources
